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Summary.-Forty-four (44) patients with Burkitt's lymphoma received identical
combination chemotherapy on the basis of body surface area. Patients with renal
dysfunction, more common in those with abdominal tumours, were at significantly
greater risk of developing severe leucopenia (<1000 cells/dl) than those with normal
renal function (P<0-0001). Similar results were seen in a series of 8 patients with
normal marrows treated with only i.v. cyclophosphamide and intrathecal methotrex-
ate. Giving a lower initial dose of cyclophosphamide seemed to reduce the risk
of severe leucopenia in 5 additional patients with evidence of renal dysfunction. The
mechanism is postulated as delayed excretion of the active metabolites of cyclo-
phosphamide. Adjustment of the chemotherapeutic dose should be considered when
treating patients with renal dysfunction.
LEUCOPENIA is a common sequela of
chemotherapy for malignant disease and
may be the factor limiting the amount of
chemotherapy tolerated. We have ob-
served a distinct pattern to the degree of
leucopenia seen in patients with Burkitt's
lymphoma treated with the same protocol
of combination chemotherapy: patients
with abdominal tumours lhad leucopenia
that was very significantly more severe
than those without abdominal tumours.
We attribute this difference largely to the
higher incidence of renal dysfunction,
overt or subelinical, in patients with ab-
dominal tumours.
PATIENTS AND METHODS
The initial observations were evaluated by
a review of the records of 44 consecutive
patients with histologically or cytologically
confirmed Burkitt's lymphoma -who met the
evaluation criteria. In these patients, treat-
rnent consisted of 3 courses of cyclophos-
phamide (CP, 700 mg/M2) and vincristin
(VN 1-4 mg/mn2) i.v., cytosine arabinoside
(AraC 100 mg/m2/day, given q6H for 3 days)
s.e. and 15 mg methotrexate (MTX) intra-
thecally. All patients were newly diagnosed
and had received no prior chemotherapy.
Allopurinol and i.v. fluids were also given to
all patients during the first course of therapy
and thereafter as clinically indicated. Follow-
ing statistical verification of the observation
by a review ofexisting records, further studies
were undertaken on the next 13 patients with
proven Burkitt lymphoma presenting for
initialtherapy. Details are given intheresults.
Patients were classified only on the basis
ofwhether abdominal tumours were detected.
Extra-abdominal Burkitt's lymphoma may
present at a variety of sites, ofwhich facial is
most common, and all but one patientwAithout
abdominal disease had facial tumours. Mar-
row examination in the retrospective portion
of the study wAas done when involvement was
suspected. No patient writh known marrow
involvement was included in the analysis.
All patients in the prospective study had
nmarrow! involvement excluded by examina-
tion of iliac-crest marrow aspiration.
Two or, more commonly, 3 x weekly,
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WBC counits were obtained. In all cases, the
WBC count had to have risen to at least
2500 cells/dl before the next course of chemo-
therapy was given; generally this occurred
16 to 18 days after i.v. chemotherapy. All
patients had to have a WBC count on or after
the 5th day after i.v. chemotherapy to be
included. Mean nadir WBC counts were com-
pared statistically using Student's t test.
Renal function was evaluated by plasma
urea and creatinine levels, and evidence of
dysfunction was accepted if either was eleva-
ted (urea: >38 mg/dl or >7-0 mM; creatinine
>1P5 mg/dl) at the onset oftherapy or during
the course of therapy. In the retrospective
portion, only urea values -were routinely
available. Statistical comparisons between
nadir WBC counts of those with and w-ithout
renal dysfunction were evaluated by the
Mann-Whitney U test.
RESULTS
Of the 44 cases initially reviewed, 27
had abdominal disease and 17 non-
abdominal. The WBC counts at the onset
of each course of therapy were similar in
those with and without abdominal
tumours. Following the first course, nadir
WBC counts in patients with abdominal
tumours (average 1320 cells/dI) were very
significantly (P<0 0005) lower than in
those without abdominal involvement
(average 2510 cells/dl). On the next 2
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FIG. 1. Aveiage nadir WBC counts after each
course of chemotherapy. Probability cal-
culated by Student's t test. E Non-
abdominal tumour; C abdominal tumour.
courses, there was no significanit differenice,
principally because nadir counts in
patients with abdominal tumours in-
creased to levels approximating those in
patients without abdominal tumours
(Fig. 1).
Abnormal renal function was more
common in patients with abdominal
tumours than in those with nonabdominal
tumours. To determine whether severe
leucopenia after chemotherapy was more
closely associated with renal function than
tumour site, the nadir WBC counts in 27
patients with normal urea levels were
compared to 13 patients with elevated
urea levels either before (7) or during (6)
the first course of therapy. Four patients
without recorded urea levels, one ofwhom
had a nadir count of <1000 cells/dl, were
excluded. The nadir counts after chemo-
therapy in patients with evidence of
abnormal renal function were significantly
lower than in those with normal renal
function, even when the patients were
stratified by site of tumour, P being
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FIG. 2. Comparison of na(lir WBC counts
in patients Nwith normal and elevated urea
levels. Piobability calculated by two-tailed
Mlann Whitney U test. * Urea level elevate(i
before therapy [0] or during therapy [0].
A, non-abdominal tumour: B, abdominal
tumour.
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<0-01 for those with abdominal tumours
and <0-05 for those with non-abdominal
tumours (Fig. 2).
Ten of 13 patients with nadir WBC
counts <1000 cells/dl on the first course
of therapy also had renal impairment,
verysignificantly (P<0-0001, Fisher exact
test) more than those with normal renal
function. In only 3 patients on the 2nd
course and one onthe 3rd course oftherapy
did the WBC count fall below I000cells/dI.
The single patient on the 3rd course had
iiadir counts below 1.000 cells/dl on each
course of therapy, and had severe renal
dysfunction (pretreatment urea initially
21
-0 mm, which rose during therapy).
A prospective study was then under-
taken on newly presenting patients '"ith
untreated abdominal Burkitt'slymphoma,
to assure that no bias was introduced by
unsuspected marrow involvement and to
determine which drug was most likely to
be responsible. Each patient was shown to
have no marrow involvement and re-
ceived only i.v. CP (1400 Mg/M2) and
intrathecal MTX (15 mg) as the first
course of therapy. The one patient with
renalimpairment ofthe first 8 studied also
had the lowest nadir WBC count (250).
To determine a safe level of initial
therapy for patients with renal dysfunc-
tion, 5 newlv presenting patients, all with
abdominal 4is-ease, normal marrow and
elevated urea and/or creatinine levels,
were placed on low-dose i.v. CP (700
Mg/M2) and intrathecal MTX (15 mg) for
the first course oftherapy. This course was
followed by 2 courses of multiple drug therapy, as in the retrospective portion of
the study.
In no one did the WBC count fall below
1000 on the first course, the average being
1810 cells/dI. During the next 2 courses of
multiple-drug therapy, no severe leuco-
penia was seen. The effectiveness and
safety of this approach is now under
study.
DISCUSSION
These data illustrate that leucopenia after chemotherapy for Burkitt's lymph-
oma is more severe in patients with
abdominal tumours than in those with
non-abdominal tumours. We attribute this
difference to a higher frequency of renal
dysfunction in patients with abdominal
tumours.
A possible explanation, linking renal
impairment with the development of
severe leueopenia, is that excretion of
active cytotoxic a ents is delaved in these
patients. This association was also ob-
served in 8 patients with normal marrows
who receivedonly CP and MTX. Reducing
the dose of CP seemed to reduce the risk
of severe leueopenia in those with renal
impairment.
CP therefore appears to be the most
likely agent responsible. After injection,
CP is metabolized to several active
alkylating agents, in a complex manner.
The composite half-life of the alkylating
agents, of which aldophosphamide is
probably the most important (Chabner
et al., 1975) is about 6-5 h on initial
exposure (Bagley et al., 1973). Between
8 and 23% of the drug is excreted
within 24 h as an active agent by
the kidneys, and in one patient, renal
failure was associated with prolonged
presence of alkylating metabolites in the
plasma and with severeleucopenia(Bagley
et al., 1973). Further studies on animal
models should be done to investigate the
excretion of CP in the presence of renal
dysfunction.
The course of renal impairment in
Burkitt's lymphoma may be mechanical
or metabolic. The kidney is one of the
most frequently involved organ sites in
patients with this tumour (Wright, 1964).
Furthermore, rapid lysis of large tumour
masses after chemotherapy can also
impair renal function by release of intra-
cellular contents and their metabolites,
such as uric acid (Krakoff & Murphy,
1968). Whatever the aetiology, the renal
dysfunction was often rapidly reversible
following chemotherapy and by the 2nd
course of therapy f-Linction was usually normal.
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in the initial course of chemotherapy for
Burkitt's lymphoma might reduce the
hazard of severe leucopenia, especially in
patients with renal impairment. After the
first course of therapy has significantly
reduced tumour volume and renal func-
tion has improved, more intensive con-
solidation therapy would bebetter toler-
ated. Renal dysfunction has not been
reported as being a significant factor in
leucopenia associated with cyclophos-
phamide. If this association is confirmed,
the hazard of severe leucopenia should be
applicable to all cancer patients with renal
dysfunction who are receiving this drug.
We thank Ms Arlene Mansky and Mr Andrew
Moulton, Peace Corps Volunteers in Ghana, for their
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